Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

The FDA has cleared Gilead’s Descovy — a top pipeline drug it spent a priority review voucher on — for HIV pre-exposure prophylaxis in a broad, but not all-encompassing, population.